Luowei  Li, Ph.D.

Luowei Li, Ph.D.

  • Center for Cancer Research
  • National Cancer Institute


Dr. Li has focused her research on understanding the role of several major signal transduction pathways on epidermal proliferation, differentiation, and transformation. She is also interested in exploring the interaction between tumor cells and their microenvironment. Recently, she has been evaluating pathway specific agents for cancer therapy.

Areas of Expertise

Cancer Therapy


Selected Publications

Direct quantification of polo-like kinase 1 activity in cells and tissues using a highly sensitive and specific ELISA assay

Park JE, Li L, Park J, Knecht R, Strebhardt K, Yuspa SH, Lee KS.
Proc. Natl. Acad. Sci. U.S.A.. 106: 1725-30, 2009. [ Journal Article ]

CLIC4 mediates and is required for Ca2+-induced keratinocyte differentiation

Suh KS, Mutoh M, Mutoh T, Li L, Ryscavage A, Crutchley JM, Dumont RA, Cheng C, Yuspa SH.
J. Cell. Sci.. 120: 2631-40, 2007. [ Journal Article ]

Reduced migration, altered matrix and enhanced TGFbeta1 signaling are signatures of mouse keratinocytes lacking Sdc1

Stepp MA, Liu Y, Pal-Ghosh S, Jurjus RA, Tadvalkar G, Sekaran A, Losicco K, Jiang L, Larsen M, Li L, Yuspa SH.
J. Cell. Sci.. 120: 2851-63, 2007. [ Journal Article ]

RasGRP3 contributes to formation and maintenance of the prostate cancer phenotype

Yang D, Kedei N, Li L, Tao J, Velasquez JF, Michalowski AM, Tóth BI, Marincsák R, Varga A, Bíró T, Yuspa SH, Blumberg PM.
Cancer Res.. 70: 7905-17, 2010. [ Journal Article ]

The skin cancer chemotherapeutic agent ingenol-3-angelate (PEP005) is a substrate for the epidermal multidrug transporter (ABCB1) and targets tumor vasculature

Li L, Shukla S, Lee A, Garfield SH, Maloney DJ, Ambudkar SV, Yuspa SH.
Cancer Res.. 70: 4509-19, 2010. [ Journal Article ]